Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Immutep stock price, quote, forecast and news

IMM.AX
AU000000IMM6
A2H81H

Price

0.37
Today +/-
-0.00
Today %
-0.68 %
P

Immutep stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Immutep stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Immutep stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Immutep stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Immutep's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Immutep Stock Price History

DateImmutep Price
8/23/20240.37 undefined
8/22/20240.37 undefined
8/21/20240.36 undefined
8/20/20240.36 undefined
8/19/20240.36 undefined
8/16/20240.36 undefined
8/15/20240.34 undefined
8/14/20240.34 undefined
8/13/20240.31 undefined
8/12/20240.31 undefined
8/9/20240.32 undefined
8/8/20240.30 undefined
8/7/20240.31 undefined
8/6/20240.29 undefined
8/5/20240.30 undefined
8/2/20240.34 undefined
8/1/20240.34 undefined
7/31/20240.35 undefined
7/30/20240.35 undefined
7/29/20240.34 undefined

Immutep Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immutep, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immutep from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immutep’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immutep. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immutep’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immutep’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immutep’s growth potential.

Immutep Revenue, EBIT and net profit per share

DateImmutep RevenueImmutep EBITImmutep Net Income
2030e468.29 M undefined0 undefined0 undefined
2029e143.7 M undefined366.94 M undefined389.49 M undefined
2028e49.72 M undefined97.98 M undefined305.8 M undefined
2027e5.08 M undefined-59.82 M undefined-44.14 M undefined
2026e5.3 M undefined-66.29 M undefined-56.41 M undefined
2025e4.53 M undefined-60.45 M undefined-53.9 M undefined
2024e4.04 M undefined-48.45 M undefined-46.59 M undefined
2023191,720 undefined-48.2 M undefined-39.9 M undefined
2022254,390 undefined-38.62 M undefined-32.21 M undefined
2021312,840 undefined-24.38 M undefined-29.9 M undefined
202013.94 M undefined-14.87 M undefined-13.47 M undefined
20196.03 M undefined-18.57 M undefined-18.34 M undefined
20187.03 M undefined-11.52 M undefined-12.75 M undefined
20174.22 M undefined-9.35 M undefined-9.37 M undefined
20162.03 M undefined-62.02 M undefined-62.02 M undefined
20151.55 M undefined-14.11 M undefined-32.15 M undefined
20142.73 M undefined-13.74 M undefined-13.34 M undefined
20134.01 M undefined-15.11 M undefined-15.23 M undefined
20124.2 M undefined-18.45 M undefined-19.94 M undefined
20111.07 M undefined-14.12 M undefined-21.08 M undefined
2010520,000 undefined-8.44 M undefined-12.16 M undefined
200930,000 undefined-2.35 M undefined-2.95 M undefined
200860,000 undefined-1.88 M undefined-1.89 M undefined
2007160,000 undefined-2.87 M undefined-3.14 M undefined
20063.88 M undefined-2.26 M undefined-4.25 M undefined
20051.07 M undefined-7.08 M undefined-6.23 M undefined
2004350,000 undefined-5.67 M undefined-4.97 M undefined

Immutep Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0000013000014421247613000445549143468
------200.00-----300.00--50.00-50.00100.00100.0075.00-14.29116.67-----25.00-880.00191.84227.27
-------------------------------
000000000000000000000-13-26-320000000
00-3-5-5-7-2-2-1-2-8-14-18-15-13-14-62-9-11-18-14-24-38-48-48-60-66-59973660
------700.00-66.67-----1,400.00-450.00-375.00-650.00-1,400.00-3,100.00-225.00-157.14-300.00-107.69----1,200.00-1,500.00-1,320.00-1,180.00197.96255.94-
0-2-3-4-4-6-4-3-1-2-12-21-19-15-13-32-62-9-12-18-13-29-32-39-46-53-56-443053890
--50.0033.33-50.00-33.33-25.00-66.67100.00500.0075.00-9.52-21.05-13.33146.1593.75-85.4833.3350.00-27.78123.0810.3421.8817.9515.225.66-21.43-793.1827.54-
1.121.523.964.876.9712.6818.5318.8425.7932.9150.356.76104.47108.27122.84160.2225.16208.66262.62324.77407.29609.91870.34900.690000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Immutep Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Immutep is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (k)OTHER REC. (M)INVENTORIES (k)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (k)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.693.043.771.582.797.533.210.671.10.9415.6455.9238.0430.0223.26.7620.8812.2423.4816.5726.3260.1380123.42
1001500000002003503805201601703.960.20.0950.2436.89101.1751.4917.4151.75
000000000.050.360.080.040.270.20.190.320.172.193.435.193.296.078.367.82
0000000000021019000000000000
0.0300.0100.020.210.0700.010.080.710.511.881.431.120.940.621.491.691.741.442.172.443.57
0.823.193.781.582.817.743.280.671.181.3816.7857.0640.931.8124.688.0221.6715.9228.6423.5431.1568.4290.81134.97
30106070605050503020100120480830580297.9631.524.226.4552.95250.57309.7308.08468.51
0000003.252.981.030.561.640000000000000
0000000000000000000006.078.367.84
01.042.062.262.31.270.670.630.580.540.50.460.230.170.1222.5520.7418.9118.2216.8415.0812.7410.449.38
000000000000000109.96109.96109.96109.96109.96109.96109.96109.96109.96
1.25000000000000000000000.450.52.52
1.281.052.122.332.361.323.973.661.641.122.240.580.7110.722.9620.8819.0418.361715.4519.6819.7220.32
2.14.245.93.915.179.067.254.332.822.519.0257.6441.6132.8125.3830.9842.5534.964740.5446.688.1110.53155.29
7.8211.1115.3118.425.3534.8537.1438.0540.4442.5767.74134.9136.71142.33149.01179.88194.53195.35213.23221.09242.99313.42367.41446.27
000000000000000000000000
-5.94-7.98-10.98-15.31-20.28-26.5-30.83-33.97-35.85-38.8-50.96-79.79-99.44-112.92-126.21-154.92-200.68-210.02-222.24-239.79-252.88-251.68-278.76-316.24
000000000000-0.12-0.15-0.21-0.2741.4741.242.5343.0943.1911.535.436.43
00000000-1.96-1.9600000000000000
1.883.134.333.095.078.356.314.082.631.8116.7855.1137.1529.2622.5924.6935.3226.5333.5224.3933.373.2794.08136.47
0.160.10.240.190.290.380.980.230.190.321.51.772.723.092.222.20.561.141.622.561.641.822.875.45
000000000020701203010080.327.6943.23189.51238.57300.47350.14357.03562.3
0.0300.220.680.350.40.050.0400.1200.71.610.440.451.030.881.452.052.51.292.963.023.58
0000000000.240.700001.0700000000
00000000000000000000129.41208.19173.38185.21
0.190.10.460.870.640.781.030.270.190.682.222.544.453.562.774.381.472.633.855.33.365.346.419.77
00000000000000005.035.786.657.648.922.611.561.04
0000000000000001.880.690000000
0.0300000.010.020.0200000.010.010.010.040.040.022.983.211.010.810.120.16
0.0300000.010.020.0200000.010.010.011.915.765.89.6210.859.933.421.681.21
0.220.10.460.870.640.791.050.290.190.682.222.544.463.572.786.297.248.4313.4816.1513.38.768.0910.98
2.13.234.793.965.719.147.364.372.822.491957.6541.6132.8325.3730.9842.5534.964740.5446.682.03102.17147.45
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Immutep provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Immutep's financial health and stability.

Assets

Immutep's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Immutep must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Immutep after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Immutep's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
000000000000000000000-29-32-39
000000000000000000000222
000000000000000000000000
000000000000422722548134
0000000000000000000001211
000000000000000000000000
000000000000000000000000
00-3-5-5-4-5-3-1-1-6-9-19-16-14-7-11-8-7-15-10-17-30-35
000000000000000000000000
0000000000-100-1112-1-1100000000
0000000000-100-1113-1-1100000000
000000000000000000000000
0000000000650003120000000
034371000211548176713019822545280
034369001121501761125018820525076
------------3.00-------1.00--1.00-1.00-2.00-3.00
000000000000000000000000
01-2-7-40-9-5-1-2-130-52-13-24-220-19-2-26-914-143
-0.77-0.92-3.49-5.23-5.67-4.75-5.07-3.34-1.56-1.88-6.56-9.8-19.69-16.55-14.33-7.84-11.34-8.51-7.79-15.33-10.86-17.66-30.25-35.44
000000000000000000000000

Immutep stock margins

The Immutep margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immutep. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immutep.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immutep's sales revenue. A higher gross margin percentage indicates that the Immutep retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immutep's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immutep's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immutep's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immutep. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immutep's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immutep Margin History

Immutep Gross marginImmutep Profit marginImmutep EBIT marginImmutep Profit margin
2030e-17,082.2 %0 %0 %
2029e-17,082.2 %255.35 %271.05 %
2028e-17,082.2 %197.08 %615.11 %
2027e-17,082.2 %-1,176.92 %-868.42 %
2026e-17,082.2 %-1,250.13 %-1,063.82 %
2025e-17,082.2 %-1,335.34 %-1,190.66 %
2024e-17,082.2 %-1,198.65 %-1,152.68 %
2023-17,082.2 %-25,139.98 %-20,809.7 %
2022-10,468.18 %-15,182.22 %-12,661.99 %
2021-4,273.75 %-7,792.48 %-9,558.44 %
2020-17,082.2 %-106.7 %-96.62 %
2019-17,082.2 %-307.65 %-303.99 %
2018-17,082.2 %-163.8 %-181.29 %
2017-17,082.2 %-221.58 %-221.91 %
2016-17,082.2 %-3,056.63 %-3,056.56 %
2015-17,082.2 %-907.92 %-2,068.14 %
2014-17,082.2 %-503.3 %-488.64 %
2013-17,082.2 %-376.81 %-379.8 %
2012-17,082.2 %-439.29 %-474.76 %
2011-17,082.2 %-1,319.63 %-1,970.09 %
2010-17,082.2 %-1,623.08 %-2,338.46 %
2009-17,082.2 %-7,833.33 %-9,833.33 %
2008-17,082.2 %-3,133.33 %-3,150 %
2007-17,082.2 %-1,793.75 %-1,962.5 %
2006-17,082.2 %-58.25 %-109.54 %
2005-17,082.2 %-661.68 %-582.24 %
2004-17,082.2 %-1,620 %-1,420 %

Immutep Stock Sales Revenue, EBIT, Earnings per Share

The Immutep earnings per share therefore indicates how much revenue Immutep has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immutep earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immutep's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immutep’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immutep's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immutep Revenue, EBIT and net profit per share

DateImmutep Sales per ShareImmutep EBIT per shareImmutep Earnings per Share
2030e0.37 undefined0 undefined0 undefined
2029e0.11 undefined0 undefined0.31 undefined
2028e0.04 undefined0 undefined0.24 undefined
2027e0 undefined0 undefined-0.03 undefined
2026e0 undefined0 undefined-0.04 undefined
2025e0 undefined0 undefined-0.04 undefined
2024e0 undefined0 undefined-0.04 undefined
20230 undefined-0.05 undefined-0.04 undefined
20220 undefined-0.04 undefined-0.04 undefined
20210 undefined-0.04 undefined-0.05 undefined
20200.03 undefined-0.04 undefined-0.03 undefined
20190.02 undefined-0.06 undefined-0.06 undefined
20180.03 undefined-0.04 undefined-0.05 undefined
20170.02 undefined-0.04 undefined-0.04 undefined
20160.01 undefined-0.28 undefined-0.28 undefined
20150.01 undefined-0.09 undefined-0.2 undefined
20140.02 undefined-0.11 undefined-0.11 undefined
20130.04 undefined-0.14 undefined-0.14 undefined
20120.04 undefined-0.18 undefined-0.19 undefined
20110.02 undefined-0.25 undefined-0.37 undefined
20100.01 undefined-0.17 undefined-0.24 undefined
20090 undefined-0.07 undefined-0.09 undefined
20080 undefined-0.07 undefined-0.07 undefined
20070.01 undefined-0.15 undefined-0.17 undefined
20060.21 undefined-0.12 undefined-0.23 undefined
20050.08 undefined-0.56 undefined-0.49 undefined
20040.05 undefined-0.81 undefined-0.71 undefined

Immutep business model

Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep is one of the most popular companies on Eulerpool.com.

Immutep SWOT Analysis

Strengths

Immutep Ltd has a strong portfolio of potential immunotherapy drugs, which have shown promising results in early stage trials. These drugs have the potential to revolutionize cancer treatment by enhancing the body's immune response to fight the disease.

The company has a highly skilled and experienced research and development team, bolstered by collaborations with renowned research institutions and academic partners. This allows Immutep to stay at the forefront of immunotherapy research and develop innovative solutions.

Immutep also possesses valuable intellectual property rights and patents, providing a competitive advantage in the rapidly growing immunotherapy market.

Weaknesses

Immutep Ltd currently relies heavily on investment and partnership funding to support its research and development efforts. A lack of diversification in funding sources could pose a risk if there are any disruptions or limitations in securing such funds.

Due to the highly specialized nature of immunotherapy, there is a risk of potential regulatory hurdles and lengthy approval processes before Immutep's drugs can be commercialized and generate revenue.

As a relatively small and emerging biopharmaceutical company, Immutep may face challenges in scaling up manufacturing capabilities and establishing a global presence to effectively compete with larger industry players.

Opportunities

The growing demand for effective cancer treatment options, especially those that harness the power of the immune system, presents a significant market opportunity for Immutep Ltd. The increasing prevalence of cancer worldwide further strengthens this potential market.

Immutep's partnerships with established pharmaceutical companies can provide access to additional resources, expertise, and distribution capabilities, facilitating the development and commercialization of its immunotherapy drugs.

Expansion into new geographic markets and diversifying the application of immunotherapy drugs beyond cancer, such as autoimmune diseases, could open up further revenue streams for the company.

Threats

The competitive landscape in the immunotherapy market is intense, with numerous companies investing heavily in research and development. Immutep Ltd faces the risk of being outpaced by competitors with more advanced therapies or greater financial resources.

Market volatility and regulatory changes can impact investment sentiment and funding availability, which may affect Immutep's ability to continue its research and development activities at the desired pace.

There is also the potential risk of unforeseen side effects or limited efficacy in clinical trials, which could hinder the approval and commercial success of Immutep's immunotherapy drugs.

Immutep Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Immutep historical P/E ratio, EBIT, and P/S ratio.

Immutep shares outstanding

The number of shares was Immutep in 2023 — This indicates how many shares 900.686 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Immutep earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Immutep's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Immutep’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Immutep's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Immutep Stock splits

In Immutep's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Immutep.

Immutep latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/2023-0.02 -0.02  (10.85 %)2024 Q2
6/30/2023-0.02 -0.02  (-1.51 %)2023 Q4
12/31/2022-0.02 -0.02  (-13.09 %)2023 Q2
6/30/2022-0.02 -0.02  (8.28 %)2022 Q4
12/31/2021-0.02 -0.02  (3.56 %)2022 Q2
6/30/2018-0.02 -0.03  (-48.26 %)2018 Q4
1

Eulerpool ESG Scorecard© for the Immutep stock

Eulerpool World ESG Rating (EESG©)

65/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees65.78
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Immutep list of shareholders

%
Name
Stocks
Change
Date
6.97 % Regal Funds Management Pty. Ltd.88,013,28088,013,2802/16/2024
4.54 % FIL Investment Management (Hong Kong) Limited57,292,912-2,334,4974/9/2024
4.41 % MLC Investments Limited55,641,79708/22/2023
4.38 % Perennial Value Management Ltd.55,278,421-4,179,8593/7/2024
4.13 % Milford Asset Management Ltd.52,120,554-9,434,5232/13/2024
3.44 % Australian Ethical Investment Ltd.43,459,437136,07310/3/2022
1.97 % Antares Capital Partners Limited24,945,77008/22/2023
1.60 % FIL Responsible Entity (Australia) Limited20,234,857-15,052,9521/11/2024
1.53 % MLC Asset Management19,299,951-179,51712/31/2023
1.08 % Firetrail Investments Pty Limited13,640,98604/30/2023
1
2
3
4

Immutep Executives and Management Board

Mr. Marc Voigt
Immutep Chief Executive Officer, Executive Director (since 2012)
Compensation 1.11 M
Dr. Frederic Triebel
Immutep Chief Scientific Officer, Executive Director (since 2014)
Compensation 744,241
Ms. Deanne Miller
Immutep Chief Operating Officer, General Counsel, Joint Company Secretary
Compensation 595,800
Mr. Peter Meyers
Immutep Independent Non-Executive Deputy Chairman of the Board
Compensation 192,284
Dr. Russell Howard
Immutep Independent Non-Executive Chairman of the Board
Compensation 171,990
1
2

Immutep Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Merck & Co Stock
Merck & Co
SupplierCustomer0,750,88-0,15-0,48-0,30-0,03
HSBC Holdings Stock
HSBC Holdings
SupplierCustomer0,68-0,42-0,53-0,88-0,790,34
Bank of New York Mellon Stock
Bank of New York Mellon
SupplierCustomer0,530,400,520,660,370,76
Laboratory Corp Stock
Laboratory Corp
SupplierCustomer0,440,270,340,770,510,81
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,42-0,08-0,36-0,37-0,70-0,17
Merck Stock
Merck
SupplierCustomer0,35-0,240,260,830,310,68
Citigroup Stock
Citigroup
SupplierCustomer0,23-0,200,160,360,750,81
Enzo Biochem Stock
Enzo Biochem
SupplierCustomer-0,14-0,340,270,480,520,71
Pfizer Stock
Pfizer
SupplierCustomer-0,50-0,65-0,380,42-0,590,38
Australian Ethical Investment Stock
Australian Ethical Investment
SupplierCustomer-0,51-0,220,300,870,640,72
1
2

Most common questions regarding Immutep

What values and corporate philosophy does Immutep represent?

Immutep Ltd is a leading biotechnology company that focuses on developing novel immunotherapeutic treatments. The company is dedicated to improving the lives of patients with cancer and autoimmune diseases through innovative research and development. Immutep's core values revolve around scientific excellence, integrity, and patient-centricity. With a commitment to advancing cutting-edge therapies, Immutep embraces a corporate philosophy centered on collaboration, innovation, and delivering breakthrough solutions. By harnessing the power of the immune system, Immutep aims to revolutionize the way diseases are treated, offering hope and improved outcomes to patients worldwide.

In which countries and regions is Immutep primarily present?

Immutep Ltd is primarily present in several countries and regions worldwide. These include Australia, where the company is headquartered, as well as the United States, Europe, and Asia-Pacific. With a focus on developing novel immunotherapy treatments, Immutep Ltd has established a global presence to reach patients and collaborate with healthcare and bio-pharmaceutical partners across these regions.

What significant milestones has the company Immutep achieved?

Immutep Ltd, a leading biotechnology company, has achieved several significant milestones. Firstly, the company successfully completed a Phase IIb clinical trial for its flagship product, Eftilagimod Alpha (efti). The trial demonstrated promising results in treating metastatic breast cancer. Secondly, Immutep entered into a strategic collaboration with major pharmaceutical companies to further develop and commercialize efti. This collaboration enhances its growth potential and market reach. Additionally, Immutep received Fast Track designation from the U.S. FDA for efti, expediting its regulatory process. These accomplishments showcase Immutep Ltd's dedication to advancing breakthrough immunotherapies and solidify its position in the biotech industry.

What is the history and background of the company Immutep?

Immutep Ltd is an Australian biotechnology company specializing in developing immunotherapy treatments for cancer and autoimmune diseases. Established in 2001, Immutep has a rich history of pioneering research and significant advancements in the field of immune-based therapies. The company's extensive expertise lies in the development of its lead product candidate, eftilagimod alpha (efti), a soluble LAG-3 protein aimed at enhancing immune responses. Immutep Ltd has collaborated with renowned pharmaceutical companies and research institutions worldwide, reinforcing its dedication to advancing immunotherapy and ultimately improving patient outcomes. With a strong focus on innovation, Immutep continues to make significant contributions in the immunotherapy space, propelling the fight against cancer and autoimmune diseases forward.

Who are the main competitors of Immutep in the market?

The main competitors of Immutep Ltd in the market include companies like Bristol-Myers Squibb, AstraZeneca, Merck, Roche, and Novartis. These companies also operate in the biopharmaceutical sector and focus on developing innovative treatments and therapies. Immutep Ltd differentiates itself through its unique therapeutic pipeline and commitment to the development of immunotherapies. With their focus on immunomodulation and immuno-oncology, Immutep Ltd aims to make a significant impact in the field of cancer treatment and autoimmune diseases, setting itself apart from its competitors.

In which industries is Immutep primarily active?

Immutep Ltd is primarily active in the biotechnology and healthcare industries.

What is the business model of Immutep?

The business model of Immutep Ltd revolves around developing and commercializing immunotherapy treatments. Immutep Ltd focuses on the development of LAG-3 related products, which play a crucial role in regulating the immune system. By leveraging its expertise and technology, the company aims to treat a wide range of diseases, including cancer and autoimmune disorders. Immutep Ltd collaborates with various partners and conducts clinical trials to evaluate the safety and effectiveness of its therapies. Through strategic partnerships and licensing agreements, the company aims to bring its innovative treatments to market, ultimately improving patient outcomes and advancing the field of immunotherapy.

What is the P/E ratio of Immutep 2024?

The Immutep P/E ratio is -7.1.

What is the P/S ratio of Immutep 2024?

The Immutep P/S ratio is 81.89.

What is the AlleAktien quality score of Immutep?

The AlleAktien quality score for Immutep is 5/10.

What is the revenue of Immutep 2024?

The expected Immutep revenue is 4.04 M AUD.

How high is the profit of Immutep 2024?

The expected Immutep profit is -46.59 M AUD.

What is the business model of Immutep

Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company has two main product platforms, the Lymphocyte Activation Gene (LAG)-3 platform and the IMP321 platform. Its leading products are IMP321, an agonistic LAG-3 antibody, and eftilagimod alpha, an IMP321-based immunotherapy. Immutep also offers services for preclinical and clinical development of immunotherapies. The company has partnerships with pharmaceutical companies such as Novartis, GlaxoSmithKline, and Eddingpharm. It has a portfolio of patents and intellectual property in the LAG-3 and IMP321 areas, and has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for the treatment of cancer and autoimmune diseases, as well as provide services for their development. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies. The answer: Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. It has two main product platforms, LAG-3 and IMP321. Leading products include IMP321 and eftilagimod alpha. The company also offers services for preclinical and clinical development of immunotherapies. It has partnerships with Novartis, GlaxoSmithKline, and Eddingpharm. Immutep has patents and intellectual property in the LAG-3 and IMP321 areas. It has licensed its LAG-3 technology for predictive diagnostics in cancer patients. Overall, Immutep aims to research, develop, and market immunotherapies for cancer and autoimmune diseases, as well as provide development services. It positions itself as a leading provider of immunotherapies based on LAG-3 and IMP321 technologies.

What is the Immutep dividend?

Immutep pays a dividend of 0 AUD distributed over payouts per year.

How often does Immutep pay dividends?

The dividend cannot currently be calculated for Immutep or the company does not pay out a dividend.

What is the Immutep ISIN?

The ISIN of Immutep is AU000000IMM6.

What is the Immutep WKN?

The WKN of Immutep is A2H81H.

What is the Immutep ticker?

The ticker of Immutep is IMM.AX.

How much dividend does Immutep pay?

Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.

What is the dividend yield of Immutep?

The current dividend yield of Immutep is .

When does Immutep pay dividends?

Immutep pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immutep?

Immutep paid dividends every year for the past 0 years.

What is the dividend of Immutep?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immutep located?

Immutep is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immutep from 8/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.

When did Immutep pay the last dividend?

The last dividend was paid out on 8/26/2024.

What was the dividend of Immutep in the year 2023?

In the year 2023, Immutep distributed 0 AUD as dividends.

In which currency does Immutep pay out the dividend?

The dividends of Immutep are distributed in AUD.

All fundamentals about Immutep

Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.